drugset / Trial / NCT01529632
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study assessed the safety and efficacy of the fixed combination product QVA149 versus the component products QAB149 and NVA237, administered concurrently, in patients that have moderate to severe chronic obstructive pulmonary disease (COPD).
Timeline
- Start
- 2012-05
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Glycopyrrolate | Small molecule | 50 ug | Inhaled |
| Comparator | Indacaterol | Other / unclassified | 150 ug | Inhaled |
| Subject | QVA149 | Other / unclassified | 50 ug | Inhaled |
| Subject | QVA149 | Other / unclassified | 110 ug | Inhaled |